Effect of Curcumin in treatment of diabetic complications

Phase 3

• Conditions: People with diabetic retinopathy.; Diabetic retinopathy; H36.0

• Registration Number: IRCT20121208011689N6
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 16 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Desire to cooperate and sign informed consent form after full knowledge of the goals and method of implementation of the study
Age between 40 to 70 years old
People with diabetic retinopathy without insulin

Exclusion Criteria

Receiving insulin
Cases of chronic diseases such as cardiovascular, renal and hepatic disorders
Malabsorption syndrome and inflammatory bowel disease (Crohn's disease, celiac sproctomy, short stomach and biliary tract jejuni-ileal syndrome)
Having certain physiological conditions like pregnancy and breastfeeding

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum level of methylglyoxal. Timepoint: First of study and in the end of study. Method of measurement: Elisa.

Secondary Outcome Measures

Name	Time	Method
Serum levels of Pentosidine. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Elisa.;Serum level of Carboxymehtyllyzine. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Elisa.;Serum level of tumor necrosis factor alpha. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Elisa.